Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma

NCT07330778 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT07330778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07330778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2026
Completion date
March 31, 2027
Enrollment
12 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate asthma